[Retracted] Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation

Figure 3

Rocaglamide administration decreases Th1 cells, cytokine expression of Th1 T cells, and accumulation of IFN-γ in allograft recipients. (a) Analyzing the proportion of CD4+ IFN-γ+ cells (Th1) in the lymph nodes using fluorochrome-conjugated-specific antibodies detected by flow cytometry. Data are presented for a representative experiment of at least three experiments (; , , and ). (b) Proportion of CD4+ IFN-γ+ cells (Th1) in splenic lymphocytes. (c) Expression of IFN-γ in the peripheral blood and culture supernatants detected by ELISA kits. (d) mRNA extracted from cardiac grafts and analyzed by qRT-PCR. The rocaglamide-treated group showed decreased IFN-γ in allografts when compared with the control group (). (e) Rocaglamide decreases the accumulation and aggregation of IFN-γ (a: 100x, 200x) in cardiac grafts. Immunohistochemical staining was performed, and the data showed the infiltration of IFN-γ was diminished in the rocagalmide-treated group.

(a)

(b)

(c)

(d)

(e)